Shao-Yong Chen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Taxane based chemotherapy is the standard of care treatment in castration resistant prostate cancer (CRPC). There is convincing evidence that taxane therapy affects androgen receptor (AR) but the exact mechanisms have to be further elucidated. Our studies identified c-jun as a crucial key player which interacts with AR and thus determines the outcome of the(More)
  • 1